cell and gene therapies

News

Bayer gains ground in two-fronted Parkinson's offensive

Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.

News

Amid BIOSECURE Act speculation, WuXi AppTec sells unit

WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum

News

Mesoblast finally pushes GvHD cell therapy over finish line

At its third attempt, Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children.

Sales & Marketing

Coming soon: The Life Sciences Industry Report 2025 – insigh...

Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends

Market Access

Overcoming regulatory hurdles to unleash breakthrough innova...

The life sciences industry is currently undergoing a significant transformation, driven by the rapid development of new modalities such as cell and gene therapies (CAGT), and substantial ne

Patients